



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Yasuomi URANO et al.**

Group Art Unit: **1614**

Application Number: **10/584,415**

Examiner: **Unassigned**

Filed: **June 26, 2006**

Confirmation Number: **9423**

For: **INHIBITOR FOR THE FORMATION OF γ -SECRETASE COMPLEX**

Attorney Docket Number: **062522**

Customer Number: **38834**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

December 18, 2006

Sir:

In compliance with 37 C.F.R. §1.56, Applicants direct the attention of the Patent and Trademark Office to the documents listed on the attached PTO/SB/08. This paper is being filed within the time periods set forth in 37 C.F.R. §1.97(b). A copy of each non-U.S. document is enclosed herewith.

If there are any fees due in connection with the filing of this paper, please charge Deposit Account No. 50-2866.

Respectfully submitted,

WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP

Sadio Kinashi

Attorney for Applicants

Registration No. 48,075

Telephone: (202) 822-1100

Facsimile: (202) 822-1111

SK/mra

Enclosures: PTO/SB/08
21 Documents

[illegible]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
	18	Robert L. Nussbaum, M.D. et al., "Alzheimer's Disease and Parkinson's Disease", The New England Journal of Medicine, April 3, 2003, page 1356-1364.	
	19	Kai Simons et al., "Cholesterol, lipid rafts, and disease", The Journal of Clinical Investigation, September 2002, vol. 110, page 597-603.	
	20	B. Wolozin', "Cholesterol and Alzheimer's disease", Biochemical Society Transactions, 2002, vol. 30, page 252-529.	
	21	George H. Rothblat et al., "Cell cholesterol efflux: integration of old and new observations provides new insights", Journal of Lipid Research, 1999, vol. 40, page 781-796.	
	22	Suzanne Wahrle et al., "Cholesterol-Dependent γ -Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains", Neurobiology of Disease, 2002, vol. 9, page 11-23.	
	23	Satoko Wada et al., " γ -Secretase Activity Is Present in Rafts but Is Not Cholesterol-Dependent", Biochemistry, 2003, vol. 42, Page 13977-13986.	
	24	Andrea Tedde et al., "Identification of New Presenilin Gene Mutations in Early-Onset Familial Alzheimer Disease", Arch Neurol, November 2003, vol. 60, page 1541-1544	
	25	Susan B. Roberts, " γ -Secretase inhibitors and Alzheimer's disease", Advanced Drug Delivery Reviews, 20020, vol. 54, page 1579-1588.	
	26	Craig A. Micchelli et al., " γ -Secretase / presenilin inhibitors for Alzheimer's disease phenocopy <i>Notch</i> mutations in <i>Drosophila</i> ", The FASEB Journal, January 2003, vol. 17, page 79-81.	
	27	Yasuko Takahashi et al., "Sulindac Sulfide Is a Noncompetitive γ -Secretase Inhibitor That Preferentially Reduces A β 42 Generation", The Journal of Biological Chemistry, May 16, 2003, vol. 278, No. 20, page 18664-18670.	
	28	Sascha Weggen et al., "A β 42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor Signaling through the APP intracellular Domain", The Journal of Biological Chemistry, August 15, 2003, vol. 278, No. 33, page 30748-30754.	
	29	Yan Zhou et al. "Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic A β 42 by Inhibition Rho", Science, November 14, 2003, vol. 302, page 1215-1217.	
	30	Michael D. Greenspan et al., "Inhibition of hydroxymethylglutaryl-coenzyme A synthase by L-659,699", Proc. Natl. Acad. Sci. USA, 1987, vol. 84, page 7488-7492.	
	31	Cheryl J. Hemingway et al., "Gemfibrozil activation of AMP-activated protein kinase", S676 Biochemical Society Transactions, 1997, page 2.	
	32	Ermond van Beek, "Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates", Biochemical and Biophysical Research Communications, 1999, vol. 264, page 108-111.	
	33	Takashi Sakurai et al., "Amyloid precursor protein and lipid rafts", 2003, vol. 54, No. 4, page 291-296.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.